Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    galantamine metabolic syndrome
Previous Study | Return to List | Next Study

Galantamine Effects in Patients With Metabolic Syndrome (GALANTA-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02283242
Recruitment Status : Completed
First Posted : November 5, 2014
Last Update Posted : February 15, 2017
Sponsor:
Collaborators:
University of Nove de Julho
Feinstein Institute for Medical Research
Information provided by (Responsible Party):
Fernanda Marciano Consolim- Colombo, University of Sao Paulo

Brief Summary:
It is recognized that inflammation can be modulated by cholinergic stimulation and that galantamine, an inhibitor of acetylcholinesterase enzyme with central nervous system action, has showed an anti-inflammatory effect, reducing body weight, abdominal fat and improvement in tissue insulin resistance in animal models. Galantamine is a safe drug that is used to treat alzheimer disease.Galantamine treatments of patients with the metabolic syndrome may represent a significant advance in management of this disease. This study aims to investigate the effects of galantamine on inflammatory markers, as well as on abdominal visceral and epicardial fat and oxidative stress in patients with metabolic syndrome. This is a pioneering study that will include expert support. The enrolling of subjects will have continuous monitoring throughout the period of treatment. The study is a double blind randomized prospective study with 60 patients with metabolic syndrome, to be randomized at ratio of 1: 1 placebo and galantamine. The dose of galanthamine is the standard clinically approved (8 and 16 mg). The tracking method include metabolic analysis, inflammatory and oxidative stress markers, hemodynamic evaluation with hear rate variability (sympatho vagal modulation) before, during and after treatment. Computerized tomography assessment of visceral abdominal and epicardial fat before and after treatment will be performed.

Condition or disease Intervention/treatment Phase
Abdominal Obesity Metabolic Syndrome Drug: Galantamine Drug: Placebo (for galantamine) Phase 4

Detailed Description:

Population: patients with metabolic syndrome; Intervention: Galantamine; Comparation: Placebo; Outcomes (primary): proinflammatory cytokines levels.

Description:

Patients with criteria of Metabolic Syndrome (with the 2005 revised NCEP ATP III criteria) will be randomized to 2 groups: use of galantamina (30 patients) or placebo (30 patients) in the following sequency:

I) 4 weeks of treatment with 8 mg of galantamine or placedo (oral ingestion capsules);

II) 8 weeks of treatment with 16 mg of galantamine or placebo (oral ingestion capsules).

Participants will receive a diary to record any symptoms that may present and will be instructed to bring it at each study visit.

Before randomization all participants will go through the following procedures:

  • Clinical and neurological evaluation;
  • Blood sample analysis of cytokines, oxidative stress and biochemical parameters;
  • Multidetector computed tomographic (MDCT) scan of abdomen (visceral - abdominal and epicardial fat) and thorax (calcium score);
  • blood pressure recording for hemodynamic evaluation and assessment of heart rate variability
  • 24h ambulatory blood pressure measurement

These procedures will be repeated at the end of the protocol.

This is a randomized controlled trial study. Blinding status: Patients, investigators, and outcome assessors.

All participants were outpatients.

The invitation to participate in the study and all the details of the protocol will be explained.

Once the patients have the criteria for inclusion, they receive the cards with capsules containing placebo or galantamine according to continuous numerical order provided by the pharmacy that prepared and randomized such substances (numbered containers).

Drug and placebo will be manipulated and encapsulated in identical packaging at the Central Pharmacy of School of Medicine, University of São Paulo.

We will use simple randomisation using a randomisation table created by computer software - graphpad Software- quickcalcs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial
Study Start Date : March 2014
Actual Primary Completion Date : March 2015
Actual Study Completion Date : February 2017


Arm Intervention/treatment
Experimental: Galantamine
  • 8 mg of Galantamine for 4 weeks
  • 16 mg Galantamine for 8 weeks
Drug: Galantamine
Oral use for 12 weeks
Other Name: Reminyl ER

Placebo Comparator: Placebo
  • 8 mg of placebo for 4 weeks
  • 16 mg placebo for 8 weeks
Drug: Placebo (for galantamine)
Oral use for 12 weeks
Other Name: Placebo




Primary Outcome Measures :
  1. Composite measure of cytokines and adipokines levels, to include IL-1, IL-6, TNF alpha, leptin and adiponectin [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Glucose, triglycerides and high density lipoprotein cholesterol levels [ Time Frame: 12 weeks ]
  2. Insulin levels [ Time Frame: 12 weeks ]
  3. Arterial blood pressure levels [ Time Frame: 12 weeks ]
  4. Heart Rate Variability [ Time Frame: 12 weeks ]
  5. Composite measure of markers of oxidative stress, to include: total amount of free radicals, malondialdehyde, allantoin, anpha-1-antiproteinase, oxidize/reduced glutatione ratio [ Time Frame: 12 weeks ]
  6. Abdominal fat levels [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion:

  • Diagnosis of Metabolic Syndrome based on recently established criteria (three abnormal findings of the following five)

    • Increased abdominal circumference ≥ 102 cm for men and 90 cm for women
    • Low plasma level of HDL cholesterol < 40md/dL for men and 50 mg/dL for women
    • Increased values for plasma triglycerides > 150 mg/dL
    • Elevated blood pressure ≥130/85 mmHg
    • Elevated level of blood sugar value to 100 mg/dL
  • Body Mass Index (BMI) between 25 and 39, with weight maintenance diet and stable for at least 6 months before study entry
  • Normal renal function and thyroid function
  • Able to participate in the study by signing an informed consent form and comply with study stages throughout its duration

Exclusion:

  • On use of antidiabetic medication
  • Triglyceride levels ≥ 400 mg/dL or use of lipid lowering medication
  • Levels of aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 200 U/L
  • Levels of aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 200 U/L
  • The office systemic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg at rest
  • BMI ≥ 40kg/m²
  • In use of antihypertensive drugs that interfere with the heart rate variability
  • On the use of drugs that have known or probable interaction with galantamine: amitriptyline, fluoxetine, fluvoxamine, ketoconazole, oxybutynin, paroxetine, quinidine
  • Already participant in regular exercise programs, defined as 90 minutes of activity per week
  • Medical history, previous diagnosis or previous supplementary examinations indicating presence of cardiac arrhythmias, coronary artery disease, valvular disease, heart failure, chronic obstructive pulmonary disease, acute or chronic liver disease, renal insufficiency, thyroid disorders, chronic inflammatory diseases, cancer, positive status for HIV, other debilitating diseases
  • Abuse of alcohol or other substances in the 12 months prior to study entry
  • History of major depression or patients with suicidal ideation
  • Personal history of eating disorder
  • Utilization of drugs for obesity
  • Use of serotonin reuptake inhibitors
  • Pregnancy or desire to become pregnant during the study period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02283242


Locations
Layout table for location information
Brazil
University of São Paulo, Heart Institute, Medical School
São Paulo, Brazil, 05403-900
Sponsors and Collaborators
University of Sao Paulo
University of Nove de Julho
Feinstein Institute for Medical Research
Investigators
Layout table for investigator information
Principal Investigator: Fernanda M Consolim Colombo, Dra University of Sao Paulo

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Fernanda Marciano Consolim- Colombo, Fernanda Marciano Consolim Colombo, MD, PhD, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT02283242    
Other Study ID Numbers: CAAE:27386114.9.0000.0068
2013/22250-9 ( Other Grant/Funding Number: Fundação de Amparo à Pesquisa do Estado de São Paulo )
First Posted: November 5, 2014    Key Record Dates
Last Update Posted: February 15, 2017
Last Verified: February 2017
Keywords provided by Fernanda Marciano Consolim- Colombo, University of Sao Paulo:
Cholinergic Antagonists
Inflammation
Oxidative Stress
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Syndrome
Glucose Metabolism Disorders
Metabolic Diseases
Galantamine
Obesity, Abdominal
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Obesity
Overnutrition
Nutrition Disorders
Cholinergic Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Parasympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Nootropic Agents